Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

Sygnis AG. (11/28/16). "Press Release: Sygnis AG Reinforces Its Proteomics Portfolio with Two Patents Granted in Europe and China". Madrid & Heidelberg.

Region Region China
Organisations Organisation Sygnis AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard)
  Group Genetrix (ES) (Group)
  Organisation 2 SIPO (State Intellectual Property Office, China)
  Group China (govt)
Products Product NVoy technology
  Product 2 functional proteomics
Persons Person Lanckriet, Heikki (Expedeon 201111 CEO + Founder)
  Person 2 de la Huerta Martinez, Pilar (Sygnis Pharma 201303– CEO + CFO before Genetrix CEO before Zeltia)
     


> Granted patents confirm innovation and novelty of proteomics product range

> Strengthens OEM deals and non-exclusive out licensing possibilities

> Enhences competitive edge supporting expansion


SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced it had been granted broad patents in Europe and China.

The patent granted by the European Patent Office (EPO) titled: “Methods and Kits for Folding Proteins in the Presence of Linear or Branched Sugar Polymers” covers SYGNIS’ NVoy technology for use in protein folding applications. Proteins require a specific three dimensional confirmation in order to be functional. When proteins of interest, such as protein drugs, are expressed in host cells they often aggregate or misfold. The Nvoy technology uses a novel type of amphipathic polymers which protect the proteins against aggregation and assist with the folding into functional proteins.

The patent granted by the State Intellectual Property Office of the People’s Republic of China (SIPO), titled: “Protein Detection Reagents and Methods with Dyes and Dextrins” covers protein detection methods. While proteins are invisible to the naked eye researchers often require accurate visualisation and quantitation of these molecules. SYGNIS offers proteomics products such as InstantBlue and Bradford Ultra which enable fast and accurate visible detection and quantitation of proteins. These products are covered by patents worldwide.

Dr. Heikki Lanckriet, Co-CEO and CSO of SYGNIS said: “These new granted patents further corroborate the innovation and novelty of SYGNIS’ proteomics product range. The broad patent coverage obtained for our products gives the Company a strong competitive edge, which will help to facilitate SYGNIS’ global expansion and the related growth in sales and revenues.”


For further information, please contact:

SYGNIS AG
Pilar de la Huerta
Co-CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com

MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 0
Email: raimund.gabriel@mc-services.eu


About SYGNIS AG: www.sygnis.com

SYGNIS AG is specialized in the development and the commercialization of proprietary technologies and offers a wide range of different commercial products addressing key challenges in molecular biology. With the acquisition of Expedeon Holdings, Ltd. based in Cambridge, UK, SYGNIS has added a complementary proteomic product portfolio. Resulting from this significant expansion, SYGNIS’ product portfolio now covers the entire workflow of molecular biology. The products are sold through a direct sales force and several distribution partners in Europe, the US and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the US as well as sales offices in Asia. The company is listed on the German Stock Exchange in Frankfurt in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###

Madrid, Spain/Heidelberg, Germany
SYGNIS AG, Waldhofer Str. 104, 69123 Heidelberg, Germany, www.sygnis.de, Tel.: + 49-6221- 3540-125, Fax: +49-6221- 3540-127

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Genetrix (ES) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px




» top